Duojia Cao

Duojia Cao is a Senior Research Scientist at Minervax ApS since January 2023 and has been a Research Engineer and Lab Manager at Lund University since April 2014, focusing on the adaptive immune response and long-term memory related to a novel vaccine against Group B Streptococci in clinical trials. Previously, Duojia Cao served as a Postdoctoral researcher at Lund University, studying B cell tolerance in rheumatoid arthritis, and as a Guest Researcher at Harvard Medical School, where monoclonal B cell hybridomas were developed for research on citrullinated epitopes. Duojia Cao completed a Ph.D. in Immunology and Rheumatology at Karolinska Institutet, where significant research was conducted on regulatory T cells and angiogenesis.